DE2532180C2 - Verwendung von Etozolin bei der Bekämpfung der Hypertonie - Google Patents
Verwendung von Etozolin bei der Bekämpfung der HypertonieInfo
- Publication number
- DE2532180C2 DE2532180C2 DE2532180A DE2532180A DE2532180C2 DE 2532180 C2 DE2532180 C2 DE 2532180C2 DE 2532180 A DE2532180 A DE 2532180A DE 2532180 A DE2532180 A DE 2532180A DE 2532180 C2 DE2532180 C2 DE 2532180C2
- Authority
- DE
- Germany
- Prior art keywords
- etozolin
- antihypertensive
- dose
- diuretic
- diuretics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960004514 etozolin Drugs 0.000 title claims description 25
- ZCKKHYXUQFTBIK-KTKRTIGZSA-N etozoline Chemical compound O=C1N(C)C(=C/C(=O)OCC)/SC1N1CCCCC1 ZCKKHYXUQFTBIK-KTKRTIGZSA-N 0.000 title claims description 25
- 206010020772 Hypertension Diseases 0.000 title claims description 5
- 239000002934 diuretic Substances 0.000 claims description 16
- 230000003276 anti-hypertensive effect Effects 0.000 claims description 12
- 230000001882 diuretic effect Effects 0.000 claims description 10
- 208000004880 Polyuria Diseases 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 229940030600 antihypertensive agent Drugs 0.000 claims description 3
- 239000002220 antihypertensive agent Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000000144 pharmacologic effect Effects 0.000 claims description 2
- 229940030606 diuretics Drugs 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 8
- 239000003792 electrolyte Substances 0.000 claims 5
- 230000003389 potentiating effect Effects 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 4
- 229960003883 furosemide Drugs 0.000 claims 4
- 230000035619 diuresis Effects 0.000 claims 3
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims 2
- 230000036772 blood pressure Effects 0.000 claims 2
- 229960004042 diazoxide Drugs 0.000 claims 2
- 230000029142 excretion Effects 0.000 claims 2
- 230000007774 longterm Effects 0.000 claims 2
- 231100000053 low toxicity Toxicity 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 230000009471 action Effects 0.000 claims 1
- 230000008901 benefit Effects 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000003292 diminished effect Effects 0.000 claims 1
- 230000000857 drug effect Effects 0.000 claims 1
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 claims 1
- 229960003199 etacrynic acid Drugs 0.000 claims 1
- 238000002474 experimental method Methods 0.000 claims 1
- 210000003722 extracellular fluid Anatomy 0.000 claims 1
- 239000005555 hypertensive agent Substances 0.000 claims 1
- 230000001631 hypertensive effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 230000005923 long-lasting effect Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 230000009955 peripheral mechanism Effects 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 238000000926 separation method Methods 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 239000007785 strong electrolyte Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001960 triggered effect Effects 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- -1 Stearic acid) Chemical class 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000005624 silicic acid group Chemical class 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2532180A DE2532180C2 (de) | 1975-07-18 | 1975-07-18 | Verwendung von Etozolin bei der Bekämpfung der Hypertonie |
| ZA763981A ZA763981B (en) | 1975-07-18 | 1976-07-05 | Antihypertonic agent |
| GR51250A GR61353B (en) | 1975-07-18 | 1976-07-13 | Antihypertonic agent |
| GB29336/76A GB1550393A (en) | 1975-07-18 | 1976-07-14 | Antihypertonic agent |
| BE168970A BE844210A (fr) | 1975-07-18 | 1976-07-16 | Procede de preparation d'une composition antihypertonique |
| AU15959/76A AU503445B2 (en) | 1975-07-18 | 1976-07-16 | Antihypertensive/antihypertonic agents |
| CA257,101A CA1060344A (en) | 1975-07-18 | 1976-07-16 | Antihypertonic agent |
| PH18693A PH13059A (en) | 1975-07-18 | 1976-07-16 | A method of reducing hypertension |
| IE1580/76A IE43611B1 (en) | 1975-07-18 | 1976-07-16 | Antihypertonic agent |
| LU75396A LU75396A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1975-07-18 | 1976-07-16 | |
| DD193930A DD126756A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1975-07-18 | 1976-07-16 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE2532180A DE2532180C2 (de) | 1975-07-18 | 1975-07-18 | Verwendung von Etozolin bei der Bekämpfung der Hypertonie |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2532180A1 DE2532180A1 (de) | 1977-02-10 |
| DE2532180C2 true DE2532180C2 (de) | 1986-12-18 |
Family
ID=5951852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2532180A Expired DE2532180C2 (de) | 1975-07-18 | 1975-07-18 | Verwendung von Etozolin bei der Bekämpfung der Hypertonie |
Country Status (11)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU531659B2 (en) * | 1979-03-22 | 1983-09-01 | Goedecke Aktiengesellschaft | (+)-(3-methyl-4-oxo - 5n-piperidinothiazolidin-2-ylidene) acetic acid esters |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3072653A (en) * | 1961-03-06 | 1963-01-08 | Warner Lamber Pharmaceutical C | 5-amino derivatives of 4-thiazolidinones and process therefor |
-
1975
- 1975-07-18 DE DE2532180A patent/DE2532180C2/de not_active Expired
-
1976
- 1976-07-05 ZA ZA763981A patent/ZA763981B/xx unknown
- 1976-07-13 GR GR51250A patent/GR61353B/el unknown
- 1976-07-14 GB GB29336/76A patent/GB1550393A/en not_active Expired
- 1976-07-16 AU AU15959/76A patent/AU503445B2/en not_active Expired
- 1976-07-16 CA CA257,101A patent/CA1060344A/en not_active Expired
- 1976-07-16 DD DD193930A patent/DD126756A5/xx unknown
- 1976-07-16 IE IE1580/76A patent/IE43611B1/en unknown
- 1976-07-16 BE BE168970A patent/BE844210A/xx not_active IP Right Cessation
- 1976-07-16 LU LU75396A patent/LU75396A1/xx unknown
- 1976-07-16 PH PH18693A patent/PH13059A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA763981B (en) | 1977-05-25 |
| AU503445B2 (en) | 1979-09-06 |
| GB1550393A (en) | 1979-08-15 |
| DD126756A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1977-08-10 |
| AU1595976A (en) | 1978-01-19 |
| IE43611L (en) | 1977-01-18 |
| GR61353B (en) | 1978-10-26 |
| BE844210A (fr) | 1976-11-16 |
| LU75396A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1977-02-28 |
| DE2532180A1 (de) | 1977-02-10 |
| PH13059A (en) | 1979-11-21 |
| IE43611B1 (en) | 1981-04-08 |
| CA1060344A (en) | 1979-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0857064B1 (de) | Stabilisierte schilddrüsenhormonhaltige arzneimittel | |
| EP0188810B1 (de) | Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Verhinderung oder Behandlung posttraumatischer Nervenschäden nach unfallbedingten Rückenmarks- und/oder Gehirntraumen | |
| DE2224534B2 (de) | Pharmazeutisches praeparat mit langsamer wirkstoffabgabe | |
| AT409083B (de) | Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung | |
| DE69814850T2 (de) | Paracetamol enthaltende schlickbare tablette | |
| DE2523998A1 (de) | Pharmazeutische zubereitung fuer die behandlung der schizophrenie | |
| EP0205865B1 (de) | Pharmazeutische Präparate mit antihypertensiver und kardioprotektiver Wirkung | |
| DE2532180C2 (de) | Verwendung von Etozolin bei der Bekämpfung der Hypertonie | |
| DE69115102T2 (de) | Stabilisator für eine 4-ethyl-2-hydroxyimino-5-nitro-3-hexenamide enthaltende Zusammensetzung und Stabilisierungsverfahren. | |
| EP0207193A2 (de) | Synergistische Kombination von Flupirtin und 4-Acetamido-phenol | |
| WO1998058639A1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DE3736866A1 (de) | Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz | |
| EP0508511B1 (de) | Erzeugnisse, enthaltend Verapamil und Trandolapril | |
| DE2755017C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE69103724T2 (de) | Pharmazeutische zusammensetzungen mit verzögerter freisetzung zur oralen verabreichung sowie deren herstellungsverfahren. | |
| DE2743702A1 (de) | Abmagerungs- oder schlankmacher- zubereitung und verfahren zu ihrer herstellung | |
| DE2621906C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE2342214C3 (de) | Heilmittel | |
| DE2416339A1 (de) | Argininpyroglutamat und verfahren zu seiner herstellung | |
| DE2823268A1 (de) | Blutdrucksenkendes mittel | |
| DE1617286C (de) | Arzneimittel auf der Basis von 4-Methyl-5-(2-chloräthyl)-thiazol | |
| DE2810051A1 (de) | Zubereitung fuer die behandlung von asthma | |
| DE2618500A1 (de) | Pharmazeutische zubereitung fuer die behandlung von bluthochdruck | |
| DE2456172C3 (de) | Arzneimittel bei rheumatischen Erkrankungen | |
| DE2823267A1 (de) | Antihypertensive praeparate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OD | Request for examination | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |